XM does not provide services to residents of the United States of America.

Indian shares tread water ahead of Fed policy decision



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>INDIA STOCKS-Indian shares tread water ahead of Fed policy decision</title></head><body>

Updates at 9:44 a.m. IST

By Bharath Rajeswaran

BENGALURU, Sept 18 (Reuters) -Indian shares were little changed on Wednesday and are expected to tread water through the session ahead of the U.S. Federal Reserve's rate decision and commentary due after market hours.

The Nifty 50 index .NSEI was up 0.05% at 25,430.05 points, while the S&P BSE Sensex .BSESN also added 0.05% at 83,113, as of 9:44 a.m. IST.

Other Asian markets were also muted. MKTS/GLOB

While the Fed is widely expected to lower rates, the size of the cut, whether 25 basis points or 50 bps, was still not clear. The odds of a 50-bps cut have climbed to 65% from 34% last week.

While a bigger cut will likely see foreign funds shifting to emerging markets such as India in search of higher returns, it has prompted fears that the Fed may have begun its easing cycle a little too late, at the cost of economic growth.

"Recent market action suggests that participants are in a wait-and-watch mode ahead of the Fed meeting," said Ajit Mishra, senior vice president of research at Religare Broking.

The Fed's reason for its decision and commentary on future policy will influence the near-term trajectory of Indian equities in terms of foreign inflows and the outlook for U.S.-dependent sectors such as IT and pharma, three analysts said.

IT stocks .NIFTYIT fell 2.4%, dragged by a 2.5% drop in Infosys INFY.NS after Macquarie said that the company will continue to lag rival Tata Consultancy Services TCS.NS.

Pharma index .NIPHARM shed 0.4%.

Overall, eight of 13 sectors logged gains. The small- .NIFSMCP100 and mid-caps .NIFMDCP100 were little changed.

Among individual stocks, Torrent Power TOPO.NS rose 3% after getting a letter of intent for a 1,500 megawatt pumped hydro storage project in the state of Maharashtra.

Emcure Pharma EMCU.NS rose 4.2% after Kotak Institutional Equities started coverage with "buy", citing likely sustained earnings growth.



Reporting by Bharath Rajeswaran in Bengaluru; Editing by Savio D'Souza, Nivedita Bhattacharjee and Sumana Nandy

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.